BenzingaAugust 14, 2026 at 7:25 AM NY2 Months Ago
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290
RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $280 to $290.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
